Mark Quick, executive vice president of corporate development at Recipharm, spoke to Pharma Field to discuss the potential implications of the UK leaving the EU in light of the new parliamentary developments.
In response to the UK’s decision to withdraw from the European Union, the European Medicines Agency (EMA) will relocate from London, UK to Amsterdam, the Netherlands in less than six months’ time. Until recently there had been no real indication as to what this would mean for the UK pharmaceutical industry, however on the 17th July 2018, MPs voted for the UK to take ‘all necessary steps’ to participate in the regulatory network operated by the EMA after it leaves the EU.
Of course, ensuring the reliable supply of medicines post-Brexit is paramount and should be one of the main focuses of the industry over the coming months.